Influenza, Influenza Virus Vaccine Adverse Reaction (Disorder), Malignancy
Conditions
Brief summary
The objective of this study is to evaluate the safety and efficacy of concurrent administration of influenza vaccine in patients receiving anti-PD1 immunotherapy (nivolumab or pembrolizumab). This will be a prospective observational study, aiming to assess patient tolerance of treatment, adverse events (incidence, grade, need for hospitalization), incidence of influenza infections, and seroconversion rates.
Interventions
BIOLOGICALinfluenza vaccination
administration of influenza vaccination
Sponsors
Wake Forest University Health Sciences
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* 18 years or older * Currently receiving immunotherapy with anti-PD-1 agents (Nivolumab or Pembrolizumab) * Have not received influenza vaccination prior to study entry date for the upcoming flu season 2016-2017 * No previous contraindication to receiving influenza vaccination * Histologically proven cancer * Expected lifetime of at least 12 weeks
Exclusion criteria
* Previous cancer * Autoimmune disease or immunosuppressive treatments * Corticosteroid treatment * Those who have a potential indication to change chemotherapy treatment in 42 days following start of treatment * History of clinically or virologically confirmed influenza infection in the previous six months * Previous contraindication to receiving influenza vaccination * Previous allergic/adverse reaction with influenza vaccination * Have received influenza vaccination prior to study entry date for upcoming 2016-2017 flu season * Positive anti influenza antibody titers as determined by the baseline blood determination (day 0)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants with confirmed influenza infection as assessed by influenza rapid antigen A and B testing, nose swab. | October 1st 2016 to March 31st 2017 | participants with confirmed influenza infection as assessed by influenza rapid antigen A and B testing, nose swab. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants with adverse events and grading of adverse event as measured by the adverse events toxicity scale. | October 1st 2016 to March 31st 2017 | participants with adverse events |
| Number of participants requiring hospitalizations for adverse events or influenza infection. | October 1st 2016 to March 31st 2017 | participants requiring hospitalizations |
| Number of participants with seroconversion as assessed by influenza A and B IgM and IgG titers. | October 1st 2016 to March 31st 2017 | participants with seroconversion |
Outcome results
None listed